Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence By Ogkologos - July 21, 2026 54 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LITESPARK-022 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Datopotamab Deruxtecan February 20, 2025 Study Examines Whether Blood Test Can Identify Early Cancers June 2, 2020 35-Year-Old Mom Has Been Living With Stage IV Breast Cancer For... March 25, 2020 Cancer in My Community: Overcoming Inequities in Care in Argentina January 3, 2023 Load more HOT NEWS Ovarian Cancer Studies Aim to Reduce Racial Disparities, Improve Outcomes Study Finds Shortcomings in Monitoring Caregivers’ Emotional Health ctDNA Analysis is Feasible for Detection of Minimal Residual Disease After... ESMO Highlights the Importance of a Strong EU Commitment Towards Robust...
